AN2 Therapeutics appoints Maggie FitzPatrick as Class II director with option grant and cash retainer

AN2 Therapeutics, Inc.

Appointed May 5, 2022; also joins nominating and corporate governance committee.
Initial stock option grant with grant-date value of $209,093 vesting monthly over 3 years.
Annual cash director retainer of $39,000 paid quarterly for board and committee service.
FitzPatrick brings experience from Johnson & Johnson, Cigna, and Exelon; also serves on VistaGen board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Margaret (Maggie) M. FitzPatrick

Class II Director

ANTX · AN2 Therapeutics, Inc.

Effective: 2022-05-05
Filed: May 9, 2022, 7:59 PM ET

On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Margaret (Maggie) M. FitzPatrick was appointed as Class II Director at AN2 Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director

View on SEC.gov

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-145000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.